MedTrace Logo

A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)

NCT05414786 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-03-10

No results posted yet for this study

Summary

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health.

Conditions

Interventions

BIOLOGICAL

eOD-GT8 60mer mRNA Vaccine (100µg)

* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart * No control group. There is no blinding and no randomization in this open label study

Sponsors & Collaborators

  • AURUM Tembisa Clinical Research

    collaborator UNKNOWN

  • Center for Family Health Research

    collaborator UNKNOWN

  • ModernaTX, Inc.

    collaborator INDUSTRY

  • International AIDS Vaccine Initiative

    lead NETWORK

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-25
Primary Completion
2023-06-30
Completion
2023-06-30
FDA Drug
Yes

Countries

  • Rwanda
  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05414786 on ClinicalTrials.gov